期刊文献+

缬沙坦分散片联合吲达帕胺治疗高血压124例临床效果分析 被引量:5

下载PDF
导出
摘要 目的观察缬沙坦分散片联合吲达帕胺对高血压的疗效及安全性。方法选取原发高血压病患者124例,随机分为单药组(62例,缬沙坦80mg/d)与联合组(62例,缬沙坦80mg/d+吲达帕胺2.5mg/d)。测量治疗前及治疗后14、28、60d的收缩压及舒张压;并观察不良反应的发生率。结果同组内治疗前同治疗后14、28、60d相比,收缩压和舒张压的差异有统计学意义(P<0.05),两组间于治疗后14d患者的收缩压和舒张压存在显著性差异(P<0.05),治疗后28d、60d两组血压的差异无统计学意义(P>0.05)。结论两组都能有效地平稳降低高血压,不良反应少,而联合组降压效果优于单药组,能早期、平稳达到血压控制目标。说明二者联用有良好的协同作用,值得临床大力推广。
作者 谢华
出处 《当代医学》 2013年第19期57-58,共2页 Contemporary Medicine
  • 相关文献

参考文献6

二级参考文献23

  • 1Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J]. Lancet, 2004, 363:2022-2031. 被引量:1
  • 2Sever P. The VALUE trial: a commentary [J]. J Renin Angiotensin Aldosterone Syst, 2004, 5 ( 3 ): 99-101. 被引量:1
  • 3Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report [J]. JAMA, 2003, 289:2560-2572. 被引量:1
  • 4Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension [J]. J Hypertens, 2003, 21:1011-1053. 被引量:1
  • 5WHO, International Society of Hypertension Writing Group.2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension[J]. J Hypertens, 2003, 21:1983-1992. 被引量:1
  • 6Weber MA, Julius S, Kjeldsen SE,et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial [J]. Lancet, 2004, 363:2049-2051. 被引量:1
  • 7Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomised to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [J]. JAMA, 2002, 288:2981-2997. 被引量:1
  • 8Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol [J]. Lancet, 2002, 359:995-1003. 被引量:1
  • 9Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 [J]. J Hypertens, 2003, 21:1055-1076. 被引量:1
  • 10Blood Pressure Lowering Treatment Trialists' Collaboration.Effect of different blood-pressure lowering regimens on major cardiovascular events:results of prospeetively-designed overviews of randomized trials [J]. Lancet, 2003, 362:1527-1535. 被引量:1

共引文献1483

同被引文献35

引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部